PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 11 | 3 | 145-153
Article title

Wpływ stężeń terapeutycznych amisulprydu i risperidonu na peroksydację lipidów ludzkiego osocza – badania in vitro

Content
Title variants
EN
The effects of therapeutic concentrations of amisulpride and risperidone on human plasma lipid peroxidation – in vitro studies
Languages of publication
EN
Abstracts
EN
Introduction: Antipsychotics may in different ways affect the oxidative stress measured by plasma lipid peroxidation. Probably some of them may intensify the oxidative balance disturbances occurring in schizophrenia. The effects of amisulpride and risperidone on redox processes are not known sufficiently yet. Aim of the study: Establishment of the effects of amisulpride and risperidone on human plasma lipid peroxidation measured by determination of the levelof thiobarbituric acid-reactive substances (TBARS), in vitro. Material and methods: Blood for the studies was collected from healthy volunteers (aged 24-26 years) for ACD solution. Active substances of the examined drugs were dissolved in 0.01% dimethylsulfoxide (DMSO) to the final concentrations (of amisulpride 578 ng/ml and risperidone 64 ng/ml) and incubated with plasma for 1 and 24 hours at 37ºC. For each experiment the control samples of plasma with DMSO (without the drug) were performed. The lipid peroxidation level was measured in plasma by determining the TBARS concentration, using the spectrophotometric method (acc. to Rice-Evans, 1991). The results were analysed using the following statistical methods: the paired Student t-test and ANOVA II variance analysis and NIR test (StatSoft Inc., Statistica v. 6.0). Results: The ANOVA II variance analysis indicated significant differences in the effects of both drugs on TBARS level (F=4.26; df=2, p<0.05). With reference to control samples, amisulpride after 24 hours’ incubation with plasma caused a significant decrease in TBARS concentration (p<0.003), whereas risperidone – an increase in TBARS concentration by 14% (p>0.05). Conclusion: Amisulpride and risperidone in concentrations corresponding to doses recommended for treatment of acute episode of schizophrenia do not induce oxidative stress measured by lipid peroxidation. Unlike risperidone, amisulpride exhibits antioxidative effects.
PL
Wprowadzenie: Leki przeciwpsychotyczne mogą wpływać w różny sposób na stres oksydacyjny, mierzony za pomocą peroksydacji lipidów osocza. Prawdopodobnie niektóre z nich mogą nasilać zaburzenia równowagi oksydacyjnej, występujące w schizofrenii. Działanie amisulprydu i risperidonu na procesy redoks nie jest dostatecznie poznane. Cel badania: Ustalenie wpływu amisulprydu i risperidonu na peroksydację lipidów ludzkiego osocza, mierzoną za pomocą oznaczenia stężenia związków reagujących z kwasem tiobarbiturowym (TBARS), w modelu in vitro. Materiał i metody: Krew do badań pobrano od zdrowych ochotników (w wieku 24-26 lat) na roztwór ACD. Substancje aktywne badanych leków rozpuszczono w 0,01% dimetylosulfotlenku (DMSO) do stężeń końcowych (amisulprydu 578 ng/ml i risperidonu 64 ng/ml) i inkubowano z osoczem 1 i 24 godziny w temperaturze 37ºC. Do każdego doświadczenia wykonano próby kontrolne osocza z DMSO (bez leku). Poziom peroksydacji lipidów mierzono w osoczu, oznaczając stężenie TBARS metodą spektrofotometryczną (wg Rice’a-Evansa, 1991). Do analizy wyników zastosowano metody statystyczne: sparowany test t-Studenta i analizę wariancji ANOVA II oraz test NIR (StatSoft Inc., Statistica v. 6.0). Wyniki: Analiza wariancji ANOVA II wykazała istotne różnice we wpływie obu leków na stężenie TBARS (F=4,26; df=2; p<0,05). W odniesieniu do prób kontrolnych amisulpryd po 24 godzinach inkubacji z osoczem spowodował istotny spadek stężenia TBARS (p<0,003), natomiast risperidon – wzrost stężenia TBARS o 14% (p>0,05). Wniosek: Amisulpryd i risperidon w stężeniach odpowiadających dawkom rekomendowanym do leczenia ostrego epizodu schizofrenii nie powodują stresu oksydacyjnego mierzonego za pomocą peroksydacji lipidów. W przeciwieństwie do risperidonu amisulpryd wywiera działanie antyoksydacyjne.
Discipline
Publisher

Year
Volume
11
Issue
3
Pages
145-153
Physical description
Contributors
  • I Katedra Psychiatrii, Klinika Zaburzeń Afektywnych i Psychotycznych Uniwersytetu Medycznego w Łodzi, Pracownia Badań Biologicznych w Psychiatrii Uniwersytetu Medycznego w Łodzi, tzn_lodz@post.pl
  • Pracownia Badań Biologicznych w Psychiatrii Uniwersytetu Medycznego w Łodzi
author
  • Pracownia Badań Biologicznych w Psychiatrii Uniwersytetu Medycznego w Łodzi
  • I Katedra Psychiatrii, Klinika Zaburzeń Afektywnych i Psychotycznych Uniwersytetu Medycznego w Łodzi
References
  • 1. Hoffer A., Osmond H., Smythies J.: Schizophrenia; a new approach. II. Result of a year’s research. J. Ment. Sci. 1954; 100: 29-45.
  • 2. Dietrich-Muszalska A., Olas B., Rabe-Jabłońska J.: Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16: 386-391.
  • 3. Dietrich-Muszalska A., Olas B.: Isoprostanes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry 2009; 10: 27-33.
  • 4. Khan M.M., Evans D.R., Gunna V. i wsp.: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002; 58: 1-10.
  • 5. Mahadik S.P., Mukherjee S., Correnti E.E., Scheffer R.: Elevated levels of lipid peroxidation products in plasma of drugnaive patients at the onset of psychosis. Schizophr. Res. 1995; 15: 66.
  • 6. Reddy R.D., Yao J.K.: Free radical pathology in schizophrenia: a review. Prostaglandins Leukot. Essent. Fatty Acids 1996; 55: 33-43.
  • 7. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P.: Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 1998; 32: 1-8.
  • 8. Yao J.K., Reddy R.D., van Kammen D.P.: Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol. Psychiatry 1999; 45: 1512-1515.
  • 9. Dietrich-Muszalska A., Olas B.: Modifications of blood platelet proteins of patients with schizophrenia. Platelets 2009; 20: 90-96.
  • 10. Dietrich-Muszalska A., Olas B., Głowacki R., Bald E.: Oxidative/ nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 2009; 59: 1-7.
  • 11. Lohr J.B., Kuczenski R., Bracha H.S. i wsp.: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry 1990; 28: 535-539.
  • 12. Yao J.K., Leonard S., Reddy R.D.: Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr. Bull. 2004; 30: 923-934.
  • 13. Sagara Y.: Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 1998; 71: 1002-1012.
  • 14. Parikh V., Khan M.M., Mahadik S.P.: Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003; 37: 43-51.
  • 15. Bai O., Wei Z., Lu W. i wsp.: Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 2002; 69: 278-283.
  • 16. Wei Z., Bai O., Richardson J.S. i wsp.: Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 2003; 73: 364-368.
  • 17. Qing H., Xu H., Wei Z. i wsp.: The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur. J. Neurosci. 2003; 17: 1563-1570.
  • 18. Kropp S., Kern V., Lange K. i wsp.: Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatry Clin. Neurosci. 2005; 17: 227-231.
  • 19. Gama C.S., Salvador M., Andreazza A.C. i wsp.: Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006; 30: 512-515.
  • 20. Zhang X.Y., Tan Y.L., Cao L.Y. i wsp.: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006; 81: 291-300.
  • 21. Dietrich-Muszalska A., Kontek B.: Lipid peroxidation in patients with schizophrenia. Psychiatry Clin. Neurosci. 2010; 64: 469-475.
  • 22. Dietrich-Muszalska A., Rabe-Jabłońska J.: Porównanie wpływu działania leków przeciwpsychotycznych – I generacji (haloperidolu) i II generacji (klozapiny, olanzapiny i risperidonu) – na peroksydację lipidów osocza in vitro. Psychiatr. Psychol. Klin. 2007; 7: 210-218.
  • 23. Dietrich-Muszalska A.: Wpływ działania haloperidolu na peroksydację lipidów w ludzkich płytkach krwi i osoczu w badaniach in vitro. Psychiatr. Psychol. Klin. 2004; 4: 150-156.
  • 24. Perrault G., Depoortere R., Morel E. i wsp.: Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997; 280: 73-82.
  • 25. Schwartz J.C., Levesque D., Martres M.P., Sokoloff P.: Dopamine D3 receptor: basic and clinical aspects. Clin. Neuropharmacol. 1993; 16: 295-314.
  • 26. Schoemaker H., Claustre Y., Fage D. i wsp.: Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 1997; 280: 83-97.
  • 27. Bressan R.A., Erlandsson K., Jones H.M. i wsp.: Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am. J. Psychiatry 2003; 160: 1413-1420.
  • 28. Martinot J.L., Paillère-Martinot M., Poirier M.F. i wsp.: In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl.) 1996; 124: 154-158.
  • 29. Müller M.J., Regenbogen B., Härtter S. i wsp.: Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J. Psychiatr. Res. 2007; 41: 673-679.
  • 30. Mauri M.C., Volonteri L.S., Colasanti A. i wsp.: Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 2007; 46: 359-388.
  • 31. Bergemann N., Kopitz J., Kress K.R., Frick A.: Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur. Neuropsychopharmacol. 2004; 14: 245-250.
  • 32. Schatzberg A.F., Nemeroff C.B. (red.): The American Psychiatric Publishing Textbook of Psychopharmacology. Wyd. 3, American Psychiatric Publishing, Inc., Arlington 2004.
  • 33. Heykants J., Huang M.L., Mannens G. i wsp.: The pharmacokinetics of risperidone in humans: a summary. J. Clin. Psychiatry 1994; 55 supl.: 13-17.
  • 34. Eerdekens M., van Hove I., Remmerie B., Mannaert E.: Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004; 70: 91-100.
  • 35. Spina E., Avenoso A., Facciolà G. i wsp.: Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl.) 2001; 153: 238-243.
  • 36. Sheehan D.V., Lecrubier Y., Sheehan K.H. i wsp.: The Mini- International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998; 59 supl. 20: 22-33.
  • 37. Rice-Evans C.A., Diplock A.T., Symons M.C.R.: Techniques in Free Radical Research. Elsevier, Amsterdam, London, New York, Tokyo 1991.
  • 38. Karatas F., Karatepe M., Baysar A.: Determination of free malondialdehyde in human serum by high-performance liquid chromatography. Anal. Biochem. 2002; 311: 76-79.
  • 39. Arvindakshan M., Sitasawad S., Debsikdar V. i wsp.: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003; 53: 56-64.
  • 40. Reinke A., Martins M.R., Lima M.S. i wsp.: Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci. Lett. 2004; 372: 157-160.
  • 41. Jacobsen J.P., Rodriguiz R.M., Mørk A., Wetsel W.C.: Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia? Neuroscience 2005; 132: 1055-1072.
  • 42. Zhang X.Y., Zhou D.F., Cao L.Y. i wsp.: Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res. 2003; 117: 85-88.
  • 43. Dakhale G., Khanzode S., Khanzode S. i wsp.: Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004; 49: 205-209.
  • 44. Pillai A., Parikh V., Terry A.V. Jr, Mahadik S.P.: Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007; 41: 372-386.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-f9b2e8f5-f515-44a1-a8df-11c4828e2b54
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.